tbuckley/cabot-search huggingface dataset:
First report of ipilimumab‐induced <scp>G</scp> rover disease
Authors: J. Munoz, B. Guillot, C. Girard, O. Dereure, A. Du‐Thanh
Journal: British Journal of Dermatology (2014)

Journal Article First report of ipilimumab‐induced Grover disease Get access J. Munoz, J. Munoz Department of Dermatology University Hospital of Montpellier University Montpellier 1 80 rue Augustin Fliche F‐34295 Montpellier Cedex 5 France Search for other works by this author on: Oxford Academic Google Scholar B. Guillot, B. Guillot Department of Dermatology University Hospital of Montpellier University Montpellier 1 80 rue Augustin Fliche F‐34295 Montpellier Cedex 5 France Search for other works by this author on: Oxford Academic Google Scholar C. Girard, C. Girard Department of Dermatology University Hospital of Montpellier University Montpellier 1 80 rue Augustin Fliche F‐34295 Montpellier Cedex 5 France Search for other works by this author on: Oxford Academic Google Scholar O. Dereure, O. Dereure Department of Dermatology University Hospital of Montpellier University Montpellier 1 80 rue Augustin Fliche F‐34295 Montpellier Cedex 5 France Search for other works by this author on: Oxford Academic Google Scholar A. Du‐Thanh A. Du‐Thanh Department of Dermatology University Hospital of Montpellier University Montpellier 1 80 rue Augustin Fliche F‐34295 Montpellier Cedex 5 France Correspondence: Aurélie Du‐Thanh. E‐mail: a-du_thanh@chu-montpellier.fr Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 171, Issue 5, 1 November 2014, Pages 1236–1237, https://doi.org/10.1111/bjd.13058 Published: 01 November 2014
Intracoronary Delivery of Adenovirus Encoding Adenylyl Cyclase VI Increases Left Ventricular Function and cAMP-Generating Capacity
Authors: N. Chin Lai, David M. Roth, Mei Hua Gao, Suzanne Fine, Brian P. Head, Jian Zhu, M. Dan McKirnan, Christopher Kwong, Nancy Dalton, Kazushi Urasawa, David A. Roth, H. Kirk Hammond
Journal: Circulation (2000)

We tested the hypothesis that intracoronary injection of a recombinant adenovirus encoding adenylyl cyclase type VI (AC(VI)) would increase cardiac function in pigs.Left ventricular (LV) dP/dt and cardiac output in response to isoproterenol and NKH477 stimulation were assessed in normal pigs before and 12 days after intracoronary delivery of histamine followed by intracoronary delivery of an adenovirus encoding lacZ (control) or AC(VI) (1.4x10(12) vp). Animals that had received AC(VI) gene transfer showed increases in peak LV dP/dt (average increase of 1267+/-807 mm Hg/s; P=0.0002) and cardiac output (average increase of 39+/-20 mL. kg(-1). min(-1); P<0.0001); control animals showed no changes. Increased LV dP/dt was evident 6 days after gene transfer and persisted for at least 57 days. Basal heart rate, blood pressure, and LV dP/dt were unchanged, despite changes in cardiac responsiveness to catecholamine stimulation. Twenty-three hour ECG recordings showed no change in mean heart rate or ectopic beats and no arrhythmias. LV homogenates from animals receiving AC(VI) gene transfer showed increased AC(VI) protein content (P=0.0007) and stimulated cAMP production (P=0.0006), confirming transgene expression and function; basal LV AC activity was unchanged. Increased cAMP-generating capacity persisted for at least 18 weeks (P<0.0002).Intracoronary injection of a recombinant adenovirus encoding AC provides enduring increases in cardiac function.
Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias
Authors: L Cro, A Guffanti, M Colombi, B Cesana, M G Grimoldi, C Patriarca, M Goldaniga, A Neri, D Intini, A Cortelezzi, A T Maiolo, L Baldini
Journal: Leukemia (2003)
A Novel Role for Mixed-Lineage Kinase-Like Mitogen-Activated Protein Triple Kinase α in Neoplastic Cell Transformation and Tumor Development
Authors: Yong-Yeon Cho, Ann M. Bode, Hideya Mizuno, Bu Young Choi, Hong Seok Choi, Zigang Dong
Journal: Cancer Research (2004)

Abstract Previously, no member of the mixed-lineage kinase (MLK) protein family was known to function as an oncogene. Here, we demonstrate that MLK-like mitogen-activated protein triple kinase (MLTK)-α, a member of the MLK family, induced neoplastic cell transformation and tumorigenesis in athymic nude mice. Introduction of small interference RNA (siRNA)-MLTK-α into MLTK-α-overexpressing cells dramatically suppressed cell transformation. Nuclear accumulation of the pHisG-MLTK-α fusion protein was observed after epidermal growth factor or 12-O-tetradecanoylphorbol-13-acetate treatment. Phosphorylation of downstream mitogen-activated protein kinase-targeted transcription factors including c-Myc, Elk-1, c-Jun, and activating transcription factor (ATF) 2 was also differentially enhanced in MLTK-α-overexpressing cells exposed to epidermal growth factor or 12-O-tetradecanoylphorbol-13-acetate stimulation compared with cells expressing mock vector or siRNA-MLTK-α. Very importantly, MLTK-α-overexpressing cells formed fibrosarcomas when injected s.c. into athymic nude mice, whereas almost no tumor formation was observed in mice that received injections of mock or siRNA-MLTK-α stably transfected cells. These results are the first to indicate that MLTK-α plays a key role in neoplastic cell transformation and cancer development.
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
Authors: M Schiff, M Keiserman, C Codding, S Songcharoen, A Berman, S Nayiager, C Saldate, T Li, R Aranda, J-C Becker, C Lin, P L N Cornet, M Dougados
Journal: Annals of the Rheumatic Diseases (2007)

<h3>Objectives:</h3> This double-blind trial evaluated the efficacy and safety of abatacept or infliximab vs placebo. The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197. <h3>Methods:</h3> Patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) were randomised 3:3:2 to abatacept (∼10 mg/kg every 4 weeks, n = 156), infliximab (3 mg/kg every 8 weeks, n = 165), or placebo (every 4 weeks, n = 110) and background MTX. Safety and efficacy were assessed throughout the study. <h3>Results:</h3> Similar patient demographics and clinical characteristics were present at baseline between groups, with mean scores of ∼1.7 for HAQ-DI and 6.8 for DAS28 (ESR). At 6 months, mean changes in DAS28 (ESR) were significantly greater for abatacept vs placebo (–2.53 vs –1.48, p&lt;0.001) and infliximab vs placebo (–2.25 vs –1.48, p&lt;0.001). For abatacept vs infliximab treatment at day 365, reductions in the DAS28 (ESR) were –2.88 vs –2.25. At day 365, the following response rates were observed for abatacept and infliximab, respectively: American College of Rheumatology (ACR) 20, 72.4 and 55.8%; ACR 50, 45.5 and 36.4%; ACR 70, 26.3 and 20.6%; low disease activity score (LDAS), 35.3 and 22.4%; DAS28-defined remission, 18.7 and 12.2%; good European League Against Rheumatism (EULAR) responses, 32.0 and 18.5%; and Health Assessment Questionnaire Disability Index (HAQ-DI), 57.7 and 52.7%. Mean changes in physical component summary (PCS) were 9.5 and 7.6, and mental component summary (MCS) were 6.0 and 4.0, for abatacept and infliximab, respectively. Over 1 year, adverse events (AEs) (89.1 vs 93.3%), serious AEs (SAEs) (9.6 vs 18.2%), serious infections (1.9 vs 8.5%) and discontinuations due to AEs (3.2 vs 7.3%) and SAEs (2.6 vs 3.6%) were lower with abatacept than infliximab. <h3>Conclusions:</h3> In this study, abatacept and infliximab (3 mg/kg every 8 weeks) demonstrated similar efficacy. Overall, abatacept had a relatively more acceptable safety and tolerability profile, with fewer SAEs, serious infections, acute infusional events and discontinuations due to AEs than the infliximab group. <h3>Trial registration number:</h3> NCT00095147.
Parameters influencing smoking cessation for asthma patients participating in a disease management program (DMP)
Authors: Arne Weber, Sabine Groos, Bernd Hagen, Jens Kretschmann, Lutz Altenhofen
Journal: European Respiratory Journal (2013)

Background and objective   In Germany (North Rhine Region) in 2006 a disease management program (DMP) for asthma has been started, focussing on patient education, standardised documentation and optimisation of quality of care. Smoking is known as a negative risk factor on pathogenesis for asthma. We want to check out which parameters support smoking cessation within the DMP.   Methods   We used standardised medical records from general practitioners in the ambulatory setting. A severity scale has been developed, which is based on different parameters. We conducted a logistic regression analysis for all adult DMP participants, who are former (n=1.216) or current (n=3.818) smokers in 2011.   Results   Among asthma patients, who take part for more than four years in a DMP, the quit rate is 38 % compared to 9 % for participants who take part for less than two years. Moreover former smokers are proportional more often treated by a pneumologist (31 vs. 23 %) and have more comorbidities (26 vs. 22 %) than current smokers. Further logistic regression analysis show an significant association for smoking cessation for older vs. younger participants [OR 1.4; CI 1.1-1.7], men vs. women [OR 1.2; CI 1.0-1.3] and patients with a high degree of asthma control vs. low level control [OR 1,5; CI 1.2-1.8]. Otherwise people with aggravated asthma symptoms have a greater probability to become a non-smoker vs. asthma patients with stable symptoms [OR 1.3; CI 1.1-1.6].   Conclusions   The results show the importance patient education for asthma patients. A long period of participation in a DMP obviously helps people stop smoking. Also the treatment by a pneumologist possibly supports smoking cessation.
Disclosing a Diagnosis of Cancer: Where and How Does It Occur?
Authors: William D. Figg, Erika K. Smith, Douglas K. Price, Bevin C. English, Paul W. Thurman, Seth M. Steinberg, Ezekiel Emanuel
Journal: Journal of Clinical Oncology (2010)

While disclosing a cancer diagnosis to a patient is common practice, how it is disclosed and the impact it has on the patient are poorly understood. We examined how cancer diagnoses were first given to patients and the impact of different aspects of disclosure on patient satisfaction.We provided a self-administered questionnaire to a total of 460 oncology patients of the National Cancer Institute (NCI) being treated at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD.Of the 437 patients who completed the survey, 54% were told their diagnosis in-person in the physician's office, 18% by phone, and 28% in the hospital. Forty-four percent of patients reported discussions of 10 minutes or fewer, 53% reported discussions lasting longer than 10 minutes, and 5% could not remember. Treatment options were not discussed for 31% of those who could clearly remember. Higher mean satisfaction scores were associated with diagnoses revealed in person rather than over the phone (68.2 +/- 1.6 v 47.2 +/- 3.7), diagnoses revealed in a personal setting rather than an impersonal setting (68.9 +/- 1.6 v 55.7 +/- 2.8), discussions lasting longer than 10 minutes rather than fewer than 10 minutes (73.5 +/- 1.9 v 54.1 +/- 2.4), and inclusion of treatment options rather than exclusion (72.0 +/- 1.9 v 50.7 +/- 3.2; P < .001 for each aspect).Physicians should disclose a cancer diagnosis in a personal setting, discussing the diagnosis and treatment options for a substantial period of time whenever possible.
In healthy primates, circulating autoreactive T cells mediate autoimmune disease.
Authors: C P Genain, D Lee-Parritz, M H Nguyen, L Massacesi, N Joshi, R Ferrante, K Hoffman, M Moseley, N L Letvin, S L Hauser
Journal: Journal of Clinical Investigation (1994)

A T cell response against myelin basic protein (MBP) is thought to contribute to the central nervous system (CNS) inflammation that occurs in the human demyelinating dis- ease multiple sclerosis.To test whether MBP-reactive T cells that are normally retrieved from the circulation are capable of inducing CNS disease, MBP-reactive T cell clones were isolated from the peripheral blood of healthy, unimmunized Callithrirjacchus (C.jacchus) marmosets.This primate spe- cies is characterized by a natural chimerism of bone marrow elements between siblings that should make possible adop- tive transfer of MBP-reactive T cells.We report that MBPreactive T cell clones efficiently and reproducibly transfer CNS inflammatory disease between members of C. jacchus chimeric sets.The demyelination that is characteristic of experimental allergic encephalomyelitis induced in C. jac- chus by immunization against human white matter did not occur after adoptive transfer of the MBP-reactive clones.It was noteworthy that encephalitogenic T cell clones were diverse in terms of their recognition of different epitopes of MBP, distinguishing the response in C. jacehus from that in some inbred rodents in which restricted recognition of MBP occurs.These findings are the first direct evidence that natural populations of circulating T cells directed against a CNS antigen can mediate an inflammatory autoimmune disease.(
Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers
Authors: Malcolm Sue-Chu, John D Brannan, Sandra D Anderson, Nora Chew, Leif Bjermer
Journal: British Journal of Sports Medicine (2010)

Background Methacholine hyperresponsiveness is prevalent in elite athletes. Comparative studies have hitherto been limited to methacholine, eucapnic voluntary hyperpnoea and exercise. This study investigated airway responsiveness to these stimuli as well as to adenosine 5′-monophosphate (AMP) and mannitol, in 58 cross-country ski athletes. Methods Exhaled nitric oxide concentration (F E NO), spirometry and bronchial challenge in random order with methacholine, AMP and mannitol were consecutively performed on three study days in the autumn. Specific IgE to eight aeroallergens and a self-completed questionnaire about respiratory symptoms, allergy and asthmatic medication were also performed on day 1. Eucapnic voluntary hyperventilation (EVH) and field exercise tests were randomly performed in 33 of the skiers on two study days in the following winter. Results Of 25 (43%) skiers with airway hyperresponsiveness (AHR), 23, five and three skiers were hyperresponsive to methacholine, AMP and mannitol, respectively. Methacholine hyperresponsiveness was more prevalent in subjects without asthma-like symptoms. The F E NO was not significantly different in skiers with and without methacholine hyperresponsiveness. Four of 14 skiers with and four of 19 skiers without methacholine hyperresponsiveness were hyperresponsive to EVH or exercise challenge. AHR to any stimulus was present in 16 asymptomatic and nine symptomatic skiers. Asthma-like symptoms were not correlated with AHR to any stimulus. Conclusions Methacholine hyperresponsiveness is more common in asymptomatic skiers and is a poor predictor of hyperresponsiveness to mannitol and hyperpnoea. The low prevalence of hyperresponsiveness to indirect stimuli may suggest differences in the pathogenesis of methacholine hyperresponsiveness in elite skiers and non-athletes.
Administration of Parenteral Iron and Mortality among Hemodialysis Patients
Authors: Harold I. Feldman, Marshall Joffe, Bruce Robinson, Jill Knauss, Borut Cizman, Wensheng Guo, Eunice Franklin-Becker, Gerald Faich
Journal: Journal of the American Society of Nephrology (2004)

ABSTRACT. The objective of this study was to evaluate whether the apparent relationship demonstrated in prior studies between iron dosing and mortality in hemodialysis (HD) patients was confounded by incomplete representation of iron dosing and morbidity over time. A cohort study was conducted among 32,566 patients who received at least 1 yr of HD at the Fresenius Medical Corporation dialysis centers during 1996 to 1997. The outcome measure was all-cause mortality through mid-1998. A total of 19 demographic, comorbidity, and laboratory characteristics were available. By proportional hazards analysis, no adverse effect on 2-year survival was found for baseline iron dose over 6 mo of ≤ 1000 mg, but statistically significant elevated mortality was demonstrated for iron doses >1000 mg to 1800 mg (adjusted hazards ratio [HR] = 1.09; 95% confidence interval [CI], 1.01 to 1.17) and >1800 mg (adjusted HR = 1.18; 95% CI, 1.09 to 1.27). However, fitting multivariable models that appropriately account for time-varying measures of iron administration as well as other fixed and time-varying measures of morbidity, the authors found no statistically significant association between any level of iron administration and mortality. This study suggests that previously observed associations between iron administration and higher mortality may have been confounded, and it provides cautious support for the safety of the judicious administration of cumulative iron doses >1000 mg over 6 mo if needed to maintain target hemoglobin levels among patients treated with maintenance HD.
Medical Audit JCAH-Style
Authors: E. William Rosenberg
Journal: JAMA (1977)

THE MEASUREMENT of medical care against objective, predetermined, explicit criteria—the so-called medical audit—has turned into an every-month, if not every-day, procedure at most American hospitals. The major credit for changing medical audit from theory to reality clearly belongs to the Joint Commission for the Accreditation of Hospitals (JCAH), which has made such activities a requirement for accreditation. <h3>The Rise of PEP</h3> In a short time, the JCAH has been able to accomplish more than had medical educators or Professional Service Review Organizations (PSRO). This achievement is due to the efforts of JCAH in designing, supplying, and promoting an appealing, prepackaged, ready-to-go system of medical audit, the Performance Evaluation Procedure (PEP).<sup>1</sup> Not only did PEP offer a fully prepared and relatively easy-to-install medical audit, it also came buttressed by a well-organized and effectively managed series of seminars where hospital trustees, administrators, and physicians were taught how to install the system
Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology
Authors: Alan L. Schwartz, Aaron Ciechanover
Journal: The Annual Review of Pharmacology and Toxicology (2008)

Cellular proteins are in a dynamic state maintained by synthesis and degradation. The ubiquitin proteolytic pathway is responsible for the degradation of the bulk of cellular proteins including short-lived, regulatory, and misfolded/denatured proteins. Ubiquitin-mediated proteolysis involves covalent attachment of multiple ubiquitin molecules to the protein substrate and degradation of the targeted protein by the 26S proteasome. Recent understanding of the molecular mechanisms involved provides a framework to understand a wide variety of human pathophysiological states as well as therapeutic interventions. This review focuses on the response to hypoxia, inflammatory diseases, neurodegenerative diseases, and muscle-wasting disorders, as well as human papillomaviruses, cervical cancer and other malignancies.
Second Cancers Following Radiotherapy for Cervical Cancer
Authors: Kleinerman Ra, Curtis Re, Boice Jd, Flannery Jt, Fraumeni Jf
Journal: JNCI Journal of the National Cancer Institute (1982)

Incidence of second primary cancers was evaluated in 7,127 women with invasive cancer of the cervix uteri, diagnosed between 1935 and 1978, and followed up to 38 years (average, 8.9 yr) in Connecticut. Among 5,997 women treated with radiation, 449 developed second primary cancers compared with 313 expected (relative risk = 1.4) on the basis of rates from the Connecticut Tumor Registry. Excess incidence was noticeable 15 years or more after radiotherapy and attributed mostly to cancers of sites in or near the radiation field, especially the bladder, kidneys, rectum, corpus uteri, and ovaries. No excess was found for these sites among the 1,130 nonirradiated women. The ratio of observed to expected cancers for these sites did not vary appreciably by age at irradiation. The data suggested that high-dose pelvic irradiation was associated with increase in cancers of the bladder, kidneys, rectum, ovaries, corpus uteri, and non-Hodgkin's lymphoma but, apparently, not leukemia, Hodgkin's disease, breast cancer, or colon cancer.
Vitamin D intake and breast cancer risk: a case–control study in Italy
Authors: M. Rossi, J.K. McLaughlin, P. Lagiou, C. Bosetti, R. Talamini, L. Lipworth, A. Giacosa, M. Montella, S. Franceschi, E. Negri, C. La Vecchia
Journal: Annals of Oncology (2008)
Myocardial perfusion defects and associated systemic ventricular dysfunction in congenitally corrected transposition of the great arteries (ccTGA)
Authors: T.S. Homung, E.J. Bernard, D.S. Colarmajer, R.B. Howman-Giles, E. Jaeggi, R.B. Chard, R.E. Hawker
Journal: Journal of the American College of Cardiology (1998)
FLUORIDE AND HEALTH: DENTAL CARIES, OSTEOPOROSIS, AND CARDIOVASCULAR DISEASE
Authors: R. G. Schamschula, D. E. Barmes
Journal: Annual Review of Nutrition (1981)

The objective of this review is to provide an overview of intermittent fasting regimens, summarize the evidence on the health benefits of intermittent fasting, and discuss physiological mechanisms by which intermittent fasting might lead to improved ...Read More
Potassium Deficiency and Cardiac Catecholamine Metabolism in the Rat
Authors: LAWRENCE R. KRAKOFF
Journal: Circulation Research (1972)

Norepinephrine metabolism, arterial blood pressure, and electrolytes were studied in rats maintained on either potassium-deficient or control diets. After 3 weeks on the test diets, the arterial blood pressure was significantly lower and the ratio of [Na] to [K] in cardiac tissue was significantly higher in potassium-deficient rats as compared to controls. Ten minutes after intravenous injection of 3 H-norepinephrine the specific activity of cardiac norepinephrine was similar in the control and potassium-deficient groups despite a significant increase in endogenous norepinephrine concentration in the potassium-deficient hearts. But 24 hours after injection, there was a significant increase in 3 H-norepinephrine specific activity, concentration, and content in the potassium-deficient group. Cardiac tissue monoamine oxidase activity was similar in both groups. The increased 3 H-norepinephrine retention and concentration and the decreased arterial blood pressure of the potassium-deficient rate suggest an impairment in norepinephrine release by the sympathetic neurons.
Lipoatrophic panniculitis and chromosome 10 abnormality
Authors: A. Martinez, M. Malone, P. Hoeger, R. Palmer, J.I. Harper
Journal: British Journal of Dermatology (2000)

We report a 3-year-old girl with a 12-month history of an acquired lipoatrophy that was rapidly progressive. Her karyotype revealed additional material on chromosome 10 at the 10q26 location. The human pancreatic lipase gene maps to chromosome 10q24–26, and we postulate an association. Lipoatrophic panniculitis describes the panniculitides in which atrophy is a feature. The classification of these diseases is confusing in the literature and the precise diagnosis still relies on a combination of clinical and laboratory assessment. Our finding of a chromosomal abnormality on chromosome 10q26 has not been described previously.